Assessment of mouse VEGF neutralization by ranibizumab and aflibercept.

Yusuke Ichiyama Riko Matsumoto Shumpei ObataOsamu SawadaYoshitsugu SaishinMasashi KakinokiTomoko SawadaMasahito Ohji

Published in: PloS one (2022)

Aflibercept but not ranibizumab interacts with mouse VEGF, both in vivo and in vitro. When conducting experiments using anti-VEGF drugs in mice, aflibercept is suitable, but ranibizumab is not.

Keyphrases

age related macular degeneration
vascular endothelial growth factor
endothelial cells
diabetic retinopathy
high fat diet induced
metabolic syndrome
skeletal muscle